reports
Northrim BanCorp Earns $13.3 Million, or $2.38 Per Diluted Share, in F...
Northrim BanCorp Earns $13.3 Million, or $2.38 Per Diluted Share, in First Quarter 2025 ANCHORAGE, Alaska, April 23, 2025 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ:NRIM) (“Northrim” or the “Company”) today reported net income of $13.3 million, or $2.38 per diluted share, in the first quarter of 2025, compared to $10.9 million, or $1.95 per diluted share, in the fourth quarter of 2024, and $8.2 million, or $1.48 per diluted share, in the first quarter a year ago. The increase in first quarter 2025 profitability as compared to the first quarter a year ago was primarily the result o...
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
- Jonathan Moreland
UCTT ULTRA CLEAN HOLDINGS INC.
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
SRE SEMPRA ENERGY
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MGPI MGP INGREDIENTS INC.
MPLX MPLX LP
PETS PETMED EXPRESS INC.
TREE LENDINGTREE INC.
STXS STEREOTAXIS
ELAN ELANCO ANIMAL HEALTH INC.
NFE NEW FORTRESS ENERGY
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
RC GRUPO RADIO CENTRO S.A.B. DE C.V.
ABCL ABCELLERA BIOLOGICS
ALIT ALIGHT
IE INC. / DELAWARE
ECAT IVANHOE ELECTRIC INC
MEGI BLACKROCK ESG CAP ALLOCATION TR
SMRT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
CUBA SMARTRENT INC
PSBD THE HERZFELD CARIBBEAN BASIN FUND
BHRB INC.
VG PALMER SQUARE CAPITAL BDC INC
BURKE HERBERT FINANCIAL SERVICES CORP
VENTURE GLOBAL INC.
- Jonathan Moreland
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
EVH
CE EVOLENT HEALTH INC CLASS A
CDXS CELANESE CORPORATION
APPS CODEXIS
AAP DIGITAL TURBINE
MEDP ADVANCE AUTO PARTS INC.
FSLR MEDPACE HOLDINGS INC.
NSA FIRST SOLAR INC.
CLF NATIONAL STORAGE AFFILIATES TRUST
RCII CLIFFS NATURAL RESOURCES INC.
STXS RENT-A-CENTER INC
GRX STEREOTAXIS
AMPY THE GABELLI HEALTHCARE & WELLNESSRX TRUST
RC AMPLIFY ENERGY
ACA GRUPO RADIO CENTRO S.A.B. DE C.V.
ENX ARCOSA
BIGC EATON VANCE NEW YORK MUNICIPAL BOND FUND
CZR BIGCOMMERCE HOLDINGS
NOG INC.
PRDO CAESARS ENTERTAINMENT INC
ABCL NORTHERN OIL AND GAS
UAN PERDOCEO EDUCATION CORP
INDI ABCELLERA BIOLOGICS
IE CVR PARTNERS LP
ECAT INDIE SEMICONDUCTOR INC
MEGI IVANHOE ELECTRIC INC
RCEL BLACKROCK ESG CAP ALLOCATION TR
SBGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
TKO AVITA MEDICAL INC
CUBA SINCLAIR INC
BHRB TKO GROUP HOLDINGS
GAM INC.
SUNS THE HERZFELD CARIBBEAN BASIN FUND
GF INC.
BURKE HERBERT FINANCIAL SERVICES CORP
GENERAL DE ALQUILER DE MAQUINARIA
SUNRISE REALTY TRUST
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
MTDR MATADOR RESOURCES COMPANY
MPC MARATHON PETROLEUM CORPORATION
LTRX LANTRONIX INC.
FRPT FRESHPET INC
EIX EDISON INTERNATIONAL
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
CMCO COLUMBUS MCKINNON CORPORATION
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
ELAN ELANCO ANIMAL HEALTH INC.
ABCL ABCELLERA BIOLOGICS
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
JANX JANUX THERAPEUTICS INC
TNYA TENAYA THERAPEUTICS INC
IE IVANHOE ELECTRIC INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
ELTX ANGION BIOMEDICA CORP
CVI CVR ENERGY
GAM INC.
GENERAL DE ALQUILER DE MAQUINARIA
AbCellera Reports Full Year 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy,” said Carl Hansen...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Resul...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were grante...
AbCellera to Participate at Upcoming Investor Conferences in March
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: 45th Annual TD Cowen Health Care Conference, March 3-5 KeyBanc Capital Markets Healthcare Forum, March 18-19 Visit for additional information. About AbCellera Biologics Inc. (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and inter...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VIAV VIAVI SOLUTIONS INC
ROLL RBC BEARINGS INCORPORATED
NRIM NORTHRIM BANCORP INC.
KEYS KEYSIGHT TECHNOLOGIES INC
JBT JOHN BEAN TECHNOLOGIES CORPORATION
GLW CORNING INC
EMN EASTMAN CHEMICAL COMPANY
CIEN CIENA CORPORATION
CAMT CAMTEK LTD.
BMI BADGER METER INC.
BEN FRANKLIN RESOURCES INC.
TATT TAT TECHNOLOGIES LTD.
INTT INTEST CORP.
PLSE PULSE BIOSCIENCES
LCUT LIFETIME BRANDS
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
SRTS SENSUS HEALTHCARE
FTG111 FLATEXDEGIRO AG
CVCO CAVCO INDUSTRIES INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
JHG JANUS HENDERSON GROUP PLC
BKR BAKER HUGHES COMPANY CLASS A
INS INTELLIGENT SYSTEMS CORP.
AVGO BROADCOM INC.
CSPI CSP INC.
TSSI TSS INC
INMB INMUNE BIO
TARS TARSUS PHARMACEUTICALS
HIMS HIMS AND HERS HEALTH INC (A)
GTLB GITLAB INC
VERV VERVE THERAPEUTICS INC
LNSR LENSAR INC
TEAM ATLASSIAN CORPORATION
BKSY BLACKSKY TECHNOLOGY INC
BBCN39 JPMORGAN BETABUILDERS CANADA BDR
VATE INNOVATE CORP
MNPR MONOPAR THERAPEUTICS INC.
Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.64 per S...
Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.64 per Share ANCHORAGE, Alaska, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.64 per share. The dividend will be payable on March 14, 2025, to shareholders of record at the close of business on March 6, 2025. “We are pleased to announce a quarterly dividend of $0.64 per share, as we continue to provide returns to our shareholders,” said Mike Huston, President and CEO. At the stock price of $78.80 per share at ...
Northrim BanCorp Earns $10.9 Million, or $1.95 Per Diluted Share, in F...
Northrim BanCorp Earns $10.9 Million, or $1.95 Per Diluted Share, in Fourth Quarter 2024, and $37.0 Million, or $6.62 Per Diluted Share, for the Year Ended December 31, 2024 ANCHORAGE, Alaska, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ:NRIM) (“Northrim” or the “Company”) today reported net income of $10.9 million, or $1.95 per diluted share, in the fourth quarter of 2024, compared to $8.8 million, or $1.57 per diluted share, in the third quarter of 2024, and $6.6 million, or $1.19 per diluted share, in the fourth quarter a year ago. The increase in the fourth quarter...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pu...
AbCellera to Report Full Year 2024 Financial Results on February 27, 2...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on . A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and ...
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell En...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets. “We are pleased to broaden our AbbVie collaboration and look forward to using AbCellera’s TCE platform to bring novel cancer immunotherapies to patients in need,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. Und...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted p...
- Jonathan Moreland
MYE MYERS INDUSTRIES INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
LTRX LANTRONIX INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
GLP GLOBAL PARTNERS LP
FCN FTI CONSULTING INC.
CVGI COMMERCIAL VEHICLE GROUP INC.
BRKR BRUKER CORPORATION
AXSM AXSOME THERAPEUTICS
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
ISTR INVESTAR HOLD
PETS PETMED EXPRESS INC.
FRD FRIEDMAN INDUSTRIES INC.
VVV VALVOLINE INC.
SACH SACHEM CAPITAL
DMLP DORCHESTER MINERALS L.P.
MBIN MERCHANTS BANCORP
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
FBRX FORTE BIOSCIENCES INC
VRM VROOM
ONEW INC.
SSSS ONEWATER MARINE
ABCL SUTTER ROCK CAPITAL CORP.
FTHM ABCELLERA BIOLOGICS
IMNM FATHOM HOLDINGS
WOLF IMMUNOME
CLVT WOLFSPEED INC
RWAY CLARIVATE PLC
ANTX RUNWAY GROWTH FINANCE CORP
NXGL AN2 THERAPEUTICS INC
HR NEXGEL INC
CARV HEALTHCARE TRUST OF AMERICA INC.
BIGZ CARVER BANCORP INC
MODD BLACKROCK INNOVATION AND GROWTH TST
PFHC MODULAR MEDICAL INC
GRNT PROFRAC HLDG CORP
NCDL GRANITE RIDGE RESOURCES INC
SPRU NUVEEN CHURCHILL DIRECT LENDING CORP
CATX SPRUCE POWER HOLDING CORP
ASMB PERSPECTIVE THERAPEUTICS
FGF INC.
GWAV ASSEMBLY BIOSCIENCES INC
FG FINANCIAL GROUP
INC.
GREENWAVE TECHNOLOGY SOLUTIONS INC
Northrim BanCorp, Inc. Appoints Shauna Hegna to its Board of Directors
Northrim BanCorp, Inc. Appoints Shauna Hegna to its Board of Directors ANCHORAGE, AK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM) announced that Shauna Hegna has been appointed to its Board of Directors. “We are pleased to have Shauna join our Board,” said Joe Schierhorn, Chairman of the Board. “Shauna has extensive expertise in shareholder services, communications, and government affairs. Her proven leadership and accomplishments will be a notable addition to our Board of Directors.” Hegna has served as President of Koniag, an Alaska Native regional ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.